Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher F Bassil

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Science Translational Medicine|March 30, 2022
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cellsMoiez Ali, Min Lu, Hazel Xiaohui Ang, et al.
Nature Medicine|February 14, 2017
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemiaNina Fenouille, Christopher F Bassil, Issam Ben-Sahra, et al.
The Journal of Experimental Medicine|June 22, 2016
Targeting MTHFD2 in acute myeloid leukemiaYana Pikman, Alexandre Puissant, Gabriela Alexe, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i>-mutant non-small cell lung cancer through covalent inhibition of KEAP1Christopher F Bassil, Gray R Anderson, Benjamin Mayro, et al.
Nature Communications|January 14, 2026
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridgeChristopher F Bassil, Kerry Dillon, Gray R Anderson, et al.
Nature Cancer|June 6, 2022
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemiaKevin H Lin, Justine C Rutter, Abigail Xie, et al.
Cancer Discovery|August 23, 2020
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Frank Ling, Camille Vaganay, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Science Translational Medicine|March 30, 2022
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cellsMoiez Ali, Min Lu, Hazel Xiaohui Ang, et al.
Nature Medicine|February 14, 2017
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemiaNina Fenouille, Christopher F Bassil, Issam Ben-Sahra, et al.
The Journal of Experimental Medicine|June 22, 2016
Targeting MTHFD2 in acute myeloid leukemiaYana Pikman, Alexandre Puissant, Gabriela Alexe, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i>-mutant non-small cell lung cancer through covalent inhibition of KEAP1Christopher F Bassil, Gray R Anderson, Benjamin Mayro, et al.
Nature Communications|January 14, 2026
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridgeChristopher F Bassil, Kerry Dillon, Gray R Anderson, et al.
Nature Cancer|June 6, 2022
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemiaKevin H Lin, Justine C Rutter, Abigail Xie, et al.
Cancer Discovery|August 23, 2020
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Frank Ling, Camille Vaganay, et al.
Pageof 2